Примери за използване на Subsequent cycles на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Subsequent cycles are 4 weeks in duration.
At the initiation of subsequent cycles of treatment.
Irinotecan dose should be reduced by 15-20% in subsequent cycles.
Dose delay for subsequent cycles due to toxicity.
B subsequent cycles of the writer included not only play, but biographies and novels.
Second episode: stop 5-FU only, at all subsequent cycles.
B subsequent cycles of the writer included not only play, but biographies and novels.
Stomatitis/mucositis grade 4 First episode: stop 5-FU only, at all subsequent cycles.
The dose can then be modified in subsequent cycles according to the woman's response.
Stomatitis/mucositis grade 4 First episode:stop 5-FU only, at all subsequent cycles.
Dosing regimen for Cycle 1 and subsequent cycles depending on response to treatment.
First episode: stop 5-FU only, at all subsequent cycles.
In subsequent cycles, brain frequency does not fall so much, so you spend more time on other levels i.
Dexamethasone should be reintroduced if symptoms develop or reappear in subsequent cycles.
Consider dose escalation up to 20 mg in subsequent cycles based on patient tolerability.
Subsequent cycles should consist of injections once weekly for 3 consecutive weeks out of every 4 weeks.
When ovulation occurs at this dosage,there is no advantage to increasing the dose in subsequent cycles of treatment.
Consider G-CSF or GMCSF in subsequent cycles for patients who develop Grade 3 or Grade 4 neutropenia.
Gazyvaro was given by intravenous infusion as a dose of 1,000 mg on Days 1, 8 and 15 of Cycle 1,on Day 1 of subsequent cycles.
Dosing regimen for subsequent cycles depending on response to treatment Patients who have achieved a CRc or CRid.
Treatment may be resumed at the next lower dose level in subsequent cycles according to the guidelines in Table 5.
Furthermore, subsequent cycles of Clenbuterol never give you nearly as good an achievement as after the first cycle. .
Therefore, the switch to MabThera subcutaneous formulation can only occur at the second or subsequent cycles of treatment.
Patients should not be treated with subsequent cycles until neutrophils recover to≥ 1.5× 109/L and platelets recover to≥ 100× 109/L.
Consider dose escalation to 1.0 mg/m2 orfurther dose reduction to 0.5 mg/m2 in subsequent cycles based on patient tolerability.
If any of these toxicities reappear in subsequent cycles in a patient exhibiting clinical benefit, the dose may be further reduced to 1 mg/ m2.
Consider dose escalation to 1.0 mg/m2 orfurther dose reduction to 0.5 mg/m2 in subsequent cycles based on patient tolerability.
If any of these toxicities reappear in subsequent cycles in a patient exhibiting clinical benefit, the dose may be further reduced(see below).